Aaron E. Miller - Publications

Publications

Partial list:

• Miller A, Bourdette D, Cohen JA, Coyle PK, Lublin F, Paty DW, Rice GP, Weinstock-Guttman B, editors. Multiple Sclerosis. New York, Continuum; 1999. pp1–196.

• Cutter GR, Baier ML, Rudick RA, Cookfair DL, Fischer JS, Petkau J, Syndulko K, Weinshenker BG, Antel JP, Confavreux C, Ellison GW, Lublin F, Miller A, Rao SM, Reingold S, Thompson A, Willoughby E. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 1999; 122: 871-882.

• Schwid S, Goodman A, Apatoff B, Coyle P, Jacobs L, Krupp L, Miller A, Wende K, Brownscheidle, New York State Multiple Sclerosis Consortium. Are quantitative functional measures more sensitive to worsening MS than traditional measures? Neurology 2000; 55: 1901-1903. PMID 11134392

• Miller A. Paroxysmal Disorders. In: Burks JS, Johnson KP, editors. Multiple Sclerosis. Diagnosis, Medical Management and Rehabilitation. New York, Demos Medical Publishing, Inc.; 2000.

• Miller A, Herndon RM. Treatment Issues. In: Kalb RC, editor. Multiple Sclerosis. The questions you have – the answers you need. Second New York, Demos Medical Publishing, Inc.; 2000.

• Miller A. Clinical Features. In: Cook SD, editor. Handbook of Multiple Sclerosis. Third New York, Marcel Dekker, Inc.; 2001.

• Boneschi FM, Rovaris M, Johnson KP, Miller A, Wolinsky JS, Ladkani D, Shifroni G, Comi G, Filippi M. Effects of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis: meta-analysis of three double-blind, randomized, placebo-controlled clinical trials. Mult. Scler. 2003; 9:349-355. PMID 12926839

• Miller AE, Coyle PK. Clinical features of multiple sclerosis. Continuum 2004; 10:38-73.

• Panitch H, Miller A, Paty D, Weinshenker B, North American Study Group on Interferon beta-1b in Secondary Progressive MS. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology 2004; 63:1788-1795.

• Miller AE. Glatiramer acetate in the treatment of multiple sclerosis. Neurol Clin 2005; 215-231. PMID 15661095

• Miller A. Ethical issues in MS clinical trials. Mult Scler 2005;11:97-98. PMID 15732276

• Wolinsky JS, Narayana PA, O’Connor P, Coyle PK, Ford C, Johnson K, Miller A, Pardo L, Kadosh S, Ladkani D; PROMiSe Trial Study Group. Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol 2007; 61:14-24. doi:10.1002/ana.21079 PMID 17262850

• Miller A. Ethical consideration in multiple sclerosis clinical trials. In Cohen JA, Rudick RA. Multiple Sclerosis Therapeutics. Third Edition. Informa UK Ltd, 2007.

• El-Moslimany H, Miller A. Escape therapies and management of multiple sclerosis. In Raine C, McFarland H, Hohlfeld R. Multiple Sclerosis: A Comprehensive Text. Elsevier Ltd. Edinburgh, 2008.